You are here

Functionalized Carbohydrate Cholesterol Lowering Agent

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1 R43 HL55044-01,
Agency Tracking Number: 29561
Amount: $99,382.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Solicitation Year: N/A
Award Year: 1995
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
1 Innovation Drive
Worcester, MA 01605
United States
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Gary Ostroff
 () -
Business Contact
Phone: () -
Research Institution

Hypercholesterolemia constitutes a major risk factor for cardiovascular disease, the leading causeAmerica. Among the lipid-lowering therapeutics, non-systemics are frequently preferred over systemicassociated with fewer potential side effects. However, even the present non-systemics have drawbacksfor new, safe and potent cholesterol-lowering drugs. We will show that functionalization of carbohydcationic hydrophobic ligands will produce such non-systemic agents with significantly higher cholestthan cholestyramine, the currently most prescribed drug. This will involve the preparation of a sericandidates and their in vitro bile acid binding testing. Selected materials will subsequently be scrneutral sterol and bile acid excretion and their plasma cholesterol-lowering potential in hamsters.hamsters indicate that the functionalization of carbohydrates can indeed substantially increase theicholesterol-lowering efficacy. Further efficacy enhancements are required which will be achieved bycarbohydrate functionalization. The identification of a safe and potent non-systemic cholesterol-lowprovide significant therapeutic benefits to a broad section of the American public.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government